神戸大学附属図書館デジタルアーカイブ
入力補助
English
カテゴリ
学内刊行物
ランキング
アクセスランキング
ダウンロードランキング
https://hdl.handle.net/20.500.14094/90007347
このアイテムのアクセス数:
48
件
(
2024-04-26
07:26 集計
)
閲覧可能ファイル
ファイル
フォーマット
サイズ
閲覧回数
説明
90007347 (fulltext)
pdf
1.34 MB
288
メタデータ
ファイル出力
メタデータID
90007347
アクセス権
open access
出版タイプ
Accepted Manuscript
タイトル
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
著者
Nagano, Tatsuya ; Tachihara, Motoko ; Nishimura, Yoshihiro
著者ID
A0860
研究者ID
1000080624684
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=a3a21385ba2a8535520e17560c007669
著者名
Nagano, Tatsuya
永野, 達也
ナガノ, タツヤ
所属機関名
医学研究科
著者ID
A1452
研究者ID
1000040448626
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=8a84f5066adebfb6520e17560c007669
著者名
Tachihara, Motoko
立原, 素子
タチハラ, モトコ
所属機関名
医学研究科
著者ID
A0759
研究者ID
1000020291453
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=cadf586815c97cd6520e17560c007669
著者名
Nishimura, Yoshihiro
西村, 善博
ニシムラ, ヨシヒロ
所属機関名
医学部附属病院
収録物名
Current Cancer Drug Targets
巻(号)
19(8)
ページ
595-630
出版者
Bentham Science Publishers
刊行日
2019
公開日
2020-08-06
抄録
Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, gefitinib, which was the first molecular targeted therapeutic agent, has actually doubled the survival time of NSCLC patients. Vigorous efforts of clinicians and researchers have revealed that lung cancer develops through the activating mutations of many driver genes including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), v-Raf murine sarcoma viral oncogene homolog B (BRAF), and rearranged during transfection (RET) genes. Although ALK, ROS1, and RET are rare genetic abnormalities, corresponding tyrosine kinase inhibitors (TKIs) can exert dramatic therapeutic effects. In addition to anticancer drugs targeting driver genes, bevacizumab specifically binds to human vascular endothelial growth factor (VEGF) and blocks the VEGF signaling pathway. The VEGF signal blockade suppresses angiogenesis in tumor tissues and inhibits tumor growth. In this review, we also explore immunotherapy, which is a promising new NSCLC treatment approach. In general, antitumor immune responses are suppressed in cancer patients, and cancer cells escape from the immune surveillance mechanism. Immune checkpoint inhibitors (ICIs) are antibodies that target the primary escape mechanisms, immune checkpoints. Patients who respond to ICIs are reported to experience longlasting therapeutic effects. A wide range of clinical approaches, including combination therapy involving chemotherapy or radiation plus adjuvant therapy, are being developed.
キーワード
Non-small cell lung cancer
EGFR
ALK
ROS-1
BRAF
RET
VEGF
Immune checkpoint inhibitor
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2019 Bentham Science Publishers. The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/openurl/content.php?genre=article&doi=10.2174/1568009619666181210114559.
詳細を表示
資源タイプ
journal article
言語
English (英語)
ISSN
1568-0096
OPACで所蔵を検索
CiNiiで学外所蔵を検索
関連情報
DOI
https://doi.org/10.2174/1568009619666181210114559
ホームへ戻る